Infections and Infectious Diseases | Phase III Developments

Pfizer Inc

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Contact Supplier

Virtual Booth

ISPE Manufacturing

Participation Not Confirmed

Update your events

Pfizer Announces Positive Top-Line Results From Phase 3 Lot Consistency Study of 20-Valent Pneumococcal Conjugate Vaccine

Lead Product(s): 20-valent pneumococcal conjugate vaccine

Therapeutic Area: Infections and Infectious Diseases

Highest Development Status: Phase III Product Type: Vaccine

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 14, 2020

Details:

In this study the 20vPnC safety profile was similar to the Prevnar 13® (pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) control group.

Pfizer Inc

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Contact Supplier

Virtual Booth

ISPE Manufacturing

Participation Not Confirmed

Update your events

Pfizer Announces Top-Line Results from Phase 3 Study of 20-Valent Pneumococcal Conjugate Vaccine

Lead Product(s): 20vPnC

Therapeutic Area: Infections and Infectious Diseases

Highest Development Status: Phase III Product Type: Vaccine

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 18, 2020

Details:

The safety objectives were met in adults 18 years of age or older demonstrating that the safety and tolerability of 20vPnC were comparable to licensed pneumococcal vaccines.

NovaLead Pharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

INDIA India

Post An Enquiry

Virtual Booth

ISPE Manufacturing

Participation Not Confirmed

Update your events

Novalead to Start Trial on Anti- Parasitic Drug for Covid-19

Lead Product(s): Nitazoxanide

Therapeutic Area: Infections and Infectious Diseases

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 25, 2020

Details:

Novalead will study the effectiveness of an anti- parasitic drug in the recovery of moderately ill Covid-19 patients. Novalead is enrolling 100 patients across six centres for the trial which is expected to start in a month’s time.

ContraFect Corporation

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

ISPE Manufacturing

Participation Not Confirmed

Update your events

ContraFect Corporation Announces Proposed Public Offering of Common Stock and Warrants

Lead Product(s): Exebacase

Therapeutic Area: Infections and Infectious Diseases

Highest Development Status: Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: Mizuho Securities USA LLC

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Public Offering May 21, 2020

Details:

ContraFect intends to use the net proceeds to continue funding its Phase 3 DISRUPT trial of exebacase (CF-301) in Staph aureus bacteremia, including right-sided endocarditis, to fund advancement of its portfolio, including IND-enabling activities for CF-370.

NovaLead Pharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

INDIA India

Post An Enquiry

Virtual Booth

ISPE Manufacturing

Participation Not Confirmed

Update your events

NovaLead Pharma to Conduct Clinical Trials for Repurposed Drug for COVID-19

Lead Product(s): NLP21

Therapeutic Area: Infections and Infectious Diseases

Highest Development Status: Phase III Product Type: Undisclosed

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 21, 2020

Details:

According to the company, NLP21 shows promising ability to act on COVID-19 through multiple relevant targets which enables its not only to prevent virus binding to the human cells but also clear damaged human cells to allow regeneration of healthier cells.

BiondVax Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

ISRAEL Israel

Post An Enquiry

Virtual Booth

ISPE Manufacturing

Participation Not Confirmed

Update your events

BiondVax Announces Receipt of $4.2 Million Through Exercise of Warrants

Lead Product(s): Proglumide

Therapeutic Area: Infections and Infectious Diseases

Highest Development Status: Phase III Product Type: Vaccine

Partner/Sponsor/Collaborator: Undisclosed

Deal Size: $4.2 million Upfront Cash: Undisclosed

Deal Type: Funding May 20, 2020

Details:

BiondVax's pivotal, Phase 3 trial in Europe is ongoing. The trial, which is assessing M‑001's ability to provide clinical protection from any circulating influenza strain, is being conducted with volunteers aged 50+ (with half aged 65+) over two flu seasons in 7 countries.

Fujifilm

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

JAPAN Japan

Post An Enquiry

Virtual Booth

ISPE Manufacturing

Participation Not Confirmed

Update your events

Fujifilm Shares Fall After Report Avigan Not Showing Clear Efficacy in Some Coronavirus Trials

Lead Product(s): Favipiravir

Therapeutic Area: Infections and Infectious Diseases

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 20, 2020

Details:

The data reported to Japan’s health ministry by hospitals treating people showing mild or no symptoms raises doubts about whether the drug can be approved by the end of this month as sought by Japan’s government.

Octapharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

South Africa

Post An Enquiry

Virtual Booth

ISPE Manufacturing

Participation Not Confirmed

Update your events

FDA Approves Octapharma USA Investigational New Drug Application for Severe COVID-19 Patients

Lead Product(s): Human Normal Immunoglobulin

Therapeutic Area: Infections and Infectious Diseases

Highest Development Status: Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 20, 2020

Details:

The objective of the randomized, double-blind, placebo-controlled, multicenter study is to determine if high-dose Octagam® 10% therapy will slow or stop respiratory deterioration in patients with severe coronavirus disease.

Cidara Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

ISPE Manufacturing

Participation Not Confirmed

Update your events

Cidara Doses First Patient In Pivotal Phase 3 Respect Trial Of Rezafungin In Patients Undergoing Allogeneic Blood And Marrow Transplantation

Lead Product(s): Rezafungin

Therapeutic Area: Infections and Infectious Diseases

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 20, 2020

Details:

First patient dosed in ReSPECT pivotal Phase 3 clinical trial evaluating the efficacy and safety of the company’s lead antifungal candidate, rezafungin, for the prevention of invasive fungal disease in patients undergoing allogeneic blood and marrow transplantation.

TASK

Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

South Africa

Post An Enquiry

Virtual Booth

ISPE Manufacturing

Participation Not Confirmed

Update your events

South Africa BCG Booster Trials Seek Low-Cost Weapon Against COVID-19

Lead Product(s): BCG vaccine

Therapeutic Area: Infections and Infectious Diseases

Highest Development Status: Phase III Product Type: Vaccine

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 19, 2020

Details:

Tests to see if the century-old Bacille Calmette-Guerin (BCG) vaccine, widely used in Africa for tuberculosis, protects against the new coronavirus have also begun in the Netherlands and Australia.

Find

Find Drugs for Infections and Infectious Diseases in Phase III Clinical Development

Phase III

A collaboration with SCORR Marketing

Product Type

Companies

Pfizer Inc

Pfizer Announces Positive Top-Line Results From Phase 3 Lot Consistency Study of 20-Valent Pneumococcal Conjugate Vaccine

Pfizer Inc

Pfizer Announces Top-Line Results from Phase 3 Study of 20-Valent Pneumococcal Conjugate Vaccine

NovaLead Pharma

Novalead to Start Trial on Anti- Parasitic Drug for Covid-19

ContraFect Corporation

ContraFect Corporation Announces Proposed Public Offering of Common Stock and Warrants

NovaLead Pharma

NovaLead Pharma to Conduct Clinical Trials for Repurposed Drug for COVID-19

BiondVax Pharmaceuticals

BiondVax Announces Receipt of $4.2 Million Through Exercise of Warrants

Fujifilm

Fujifilm Shares Fall After Report Avigan Not Showing Clear Efficacy in Some Coronavirus Trials

Octapharma

FDA Approves Octapharma USA Investigational New Drug Application for Severe COVID-19 Patients

Cidara Therapeutics

Cidara Doses First Patient In Pivotal Phase 3 Respect Trial Of Rezafungin In Patients Undergoing Allogeneic Blood And Marrow Transplantation

TASK

South Africa BCG Booster Trials Seek Low-Cost Weapon Against COVID-19